Journal article
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: Low-dose study
J Proietto, A Rissanen, JB Harp, N Erondu, Q Yu, S Suryawanshi, ME Jones, AO Johnson-Levonas, SB Heymsfield, KD Kaufman, JM Amatruda
International Journal of Obesity | NATURE PUBLISHING GROUP | Published : 2010
DOI: 10.1038/ijo.2010.38
Abstract
Objective:To evaluate the weight loss efficacy, safety and tolerability of taranabant, a CB1R inverse agonist, in obese and overweight patients.Design: Multicenter, double-blind, randomized, placebo-controlled study.Subjects: Patients 18 years old, BMI 27-43 kg m 2, were randomized to placebo (n209) or taranabant 0.5 mg (n207), 1 mg (n208) or 2 mg given orally once daily (n417) for 52 weeks.Measurements:Key efficacy measurements included body weight (BW), waist circumference (WC), lipid endpoints and glycemic endpoints.Results:Based on a last observation carried forward analysis of the all-patients-treated population, mean change in BW for taranabant 0.5, 1, and 2 mg and placebo was 5.4, 5.3..
View full abstractGrants
Funding Acknowledgements
The study was funded by Merck & Co. The authors JBH, NE, QY, SS, MEJ, AOJ-L, SBH, KDK and JMA are employees of Merck & Co. Inc., and may hold stock in that company. JP is a member of a Merck Diabetes and Obesity Global Expert Committee.